Mining FDA’s AER Database: Heaven for Hypochondriacs, Hell for Pharma
A story in yesterday's WSJ Health featured AdverseEvents Inc., a start-up company that has streamlined the FDA's "often impenetrable" adverse drug event database and...
The Coming Pharma Digital Depression Caused by Facebook
P&G Discovers It's "Free" to Advertise on Facebook!
That's the gist of an article written by Jim Edwards over at Business Insider - Advertising (read...
Paula Deen & Victoza: Brilliant or Dumb?
OK. I've written so much about Novo Nordisk's deal with celebrity chef Paula Deen that even I am tempted to say "Enough already! Move...
Allergan “Badly Let Down” by Employee Tweet
The Prescription Medicines Code of Practice Authority (PMCPA) ruled that Allergan breached UK pharma's self-regulatory Code of Practice because an employee accidentally tweeted publicly...
Taking the “Cool” Way Out of Having Rx Product Convos on Social Media
I have criticized pharma companies for mentioning Rx brand product names via social media. Mostly because they forget to include fair balance or don't...
Ranking Pharma’s Social Media Presence: Tracking a Moving Target!
A conversation with Christopher Wooden, Vice President, Global Sales at Cegedim Strategic Data (CSD), about CSD's desk research that tabulated how the top 100 pharmaceutical companies rank in terms of their Social media exposure (likes, posts, tweets, followers) on two of the most important social network websites: Facebook and Twitter.
Should Pharma Disclose Payments to Celebrity Spokespeople?
In my podcast interview of Ambre Morley (listen here or read it here: "Novo Nordisk Defends Choice of Paula Deen as Diabetes Spokesperson"), Associate...
Is There a Cure for Mediocre Pharma Mobile Apps?: Listen Up, New Marketing Grads!
Mobile is the new 'shiny thing' of interest to pharmaceutical marketers. However, most pharma mobile apps that I have seen are pretty mundane as far as marketing/advertising is concerned. What's it going to take to make these apps more interesting and useful?
FDA Social Media Guidelines May Be Moot: If This Court Decision Holds Up
Drugmakers dissatisfied with the FDA's use of guidances as a form of policymaking -- including long-awaited guidance for use of social media by the pharmaceutical industry -- could find legal ammunition against the practice. This article presents the relevant case information.
FDA Guidance on Responding to Unsolicited Requests for Off-Label Information
Two days after Christmas, on December 27, 2011, while most of us were still on vacation, the FDA quietly issued
